	FORM 4
	Check this box if no longer subject to Section 16.
	Form 4 or Form 5 obligations may continue. See
	Instruction 1(b).
	Check this box to indicate that a transaction was
	made pursuant to a contract, instruction or written
	plan for the purchase or sale of equity securities of
	the issuer that is intended to satisfy the affirmativ
	defense conditions of Rule 10b5-1(c). See
	Instruction 10.
(Print	or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per	
response	0.5

(11iii of Type Responses)				
1. Name and Address of Re Phillip Frost, M.D., ET AL			2. Issuer Name and Ticker or Trading Symbol OPKO Health, Inc. [OPK]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner
(Last) (First) (Middle) OPKO Health, Inc. 4400 Biscayne Blvd.			3. Date of Earliest Transaction (Month/Day/Year) 11/08/2024	X Officer (give title below) Other (specify below) CEO & Chairman
(Street) Miami, FL 33137			4. If Amendment, Date Original Filed (Month/Day/Year) 11/08/2024	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person
(City)	(State)	(Zip)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month /Day/Year)	Execution Co	Code		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form:	Beneficial
			Code	V	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock	11/08/2024		Р		280,183	A	\$ 1.5045 (1)	211,512,405	I	See Footnote (2)
Common Stock								30,127,177	I	See Footnote (3)
Common Stock								3,568,951 ⁽⁴⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	or Exercise	3. Transaction Date (Month /Day/Year)	3A. Deemed Execution Date, if any (Month/Day /Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		(Instr. 5)	of Derivative Securities Beneficially	Ownership Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Following Reported	Direct (D) or Indirect (I) (Instr. 4)	

				_						
	nd Address of Reporting Person* rost, M.D., ET AL									
	(First) Jealth, Inc. Scayne Blvd.		(Middle)							
(Street) Miami	FL		33137							
(City)	(State)		(Zip)							
Relationsh	ip of Reporting Person(s) to Issue	er		,						
X X	Director Officer (give title below) CEO & Chairman	X	10% Owner Other (specify below)							
	nd Address of Reporting Person* mma Investments Trust									
	(First) Jealth, Inc. Scayne Blvd.		(Middle)							
(Street) Miami	FL		33137							
(City)	(State)		(Zip)							
Relationship of Reporting Person(s) to Issuer										
	Director Officer (give title below)	X	10% Owner Other (specify below)	_ 						

Explanation of Responses:

- 1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.455 to \$1.545, inclusive. The reporting person undertakes to provide to OPKO Health, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.
- 2. The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- 3. These securities are held by Frost Nevada Investments Trust, of which the Reporting Person is the trustee and Frost-Nevada, L.P. is the sole and exclusive beneficiary. The Reporting Person is one of seven limited partners of Frost-Nevada, L.P. and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- 4. Due to a scrivener's error, the total number of securities directly owned by the reporting person was erroneously reported on a Form 4 filed on November 8, 2024. This Form 4 corrects the total number of the securities owned directly by the reporting person. No other information has changed.

	Phillip Frost, M.D., Individually and as Trustee	11/20/2024
•	** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

JOINT FILER INFORMATION

Name: Frost Gamma Investments Trust

Address:

4400 Biscayne Blvd. Miami, FL 33137

Designated Filer: Phillip Frost, M.D.

Issuer Name and Ticker Symbol: OPKO Health, Inc. (OPK)

Date of Earliest Transaction: November 20, 2024

Relationship to Issuer: 10% Owner

FROST GAMMA INVESTMENTS TRUST

By: /s/ Phillip Frost, M.D., as Trustee Phillip Frost, M.D., Trustee